Chamberland M E, Epstein J, Dodd R Y, Persing D, Will R G, DeMaria A, Emmanuel J C, Pierce B, Khabbaz R
Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Emerg Infect Dis. 1998 Jul-Sep;4(3):410-1. doi: 10.3201/eid0403.980317.
Since blood is a biologic product, it is unlikely that the risk for transfusion-transmitted infection will ever be reduced to zero. The approach to emerging infections associated with transfusion of blood and blood products includes assessing the transmissibility of the agent by this route; developing effective prevention strategies, including screening tests and donor deferral policies; improving viral and bacterial inactivation procedures; and surveillance for known, as well as emerging and poorly characterized, transfusion-transmitted agents. Vigilance is needed to help ensure proper balance between safety and the availability of blood. Finally, vigilance needs to extend to the developing world, where the basic elements to reduce transfusion-transmitted infections and systems of disease surveillance are often not available.
由于血液是一种生物制品，输血传播感染的风险不太可能降至零。应对与输血及血液制品相关的新发感染的方法包括评估病原体通过该途径的传播性；制定有效的预防策略，包括筛查检测和献血者延期政策；改进病毒和细菌灭活程序；以及监测已知的、新发的和特征不明的输血传播病原体。需要保持警惕，以确保在安全与血液供应之间取得适当平衡。最后，警惕需要扩展到发展中世界，在那里往往缺乏减少输血传播感染的基本要素和疾病监测系统。
